Next Story
13 Jan 2026
Wockhardt Files EMA Application for Novel Antibiotic WCK 5222
Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 ..

